Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
|
|
Kintara Therapeutics, Inc. (DMPI)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/10/2023 |
8-K
| Quarterly results |
| 10/04/2023 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 09/26/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 06/30/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders... |
| 06/02/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/25/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/11/2023 |
8-K
| Quarterly results|
Docs:
|
"SUMMARY OF FINANCIAL RESULTS FOR FISCAL YEAR 2023 THIRD QUARTER ENDED MARCH 31, 2023 As of March 31, 2023, Kintara had cash and cash equivalents of approximately $3.0 million. For the three months ended March 31, 2023, Kintara reported a net loss of approximately $3.3 million, or $1.94 per share, compared to a net loss of approximately $5.4 million, or $5.45 per share, for the three months ended March 31, 2022. For the nine months ended March 31, 2023, Kintara reported a net loss of approximately $11.3 million, or $7.32 per share, compared to a net loss of approximately $17.2 million, or $22.39 per share, for the nine months ended March 31, 2022. The decreased net losses for the three and nine months ended March 31, 2023 compared to the three and nine months ended March 31, 2022 was largel..." |
|
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/09/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 03/31/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 03/31/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/31/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 03/21/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 02/14/2023 |
8-K
| Quarterly results|
Docs:
|
"SUMMARY OF FINANCIAL RESULTS FOR FISCAL YEAR 2023 SECOND QUARTER ENDED DECEMBER 31, 2022 As of December 31, 2022, Kintara had cash and cash equivalents of approximately $4.9 million. For the three months ended December 31, 2022, Kintara reported a net loss of approximately $3.5 million, or $2.10 per share, compared to a net loss of approximately $5.9 million, or $6.07 per share, for the three months ended December 31, 2021. For the six months ended December 31, 2022, Kintara reported a net loss of approximately $8.1 million, or $5.42 per share, compared -1- to a net loss of approximately $11.9 million, or $17.30 per share, for the six months ended December 31, 2021. The decreased net losses for the three and six months ended December 31, 2022 compared to the three and six months ended Dece..." |
|
| 02/14/2023 |
10-Q
| Quarterly Report for the period ended December 31, 2022 |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 12/05/2022 |
8-K
| Quarterly results |
| 11/30/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
8-K
| Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea... |
| 11/09/2022 |
8-K
| Quarterly results |
| 11/09/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 10/19/2022 |
8-K
| Quarterly results |
| 09/27/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 09/27/2022 |
8-K
| Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits I...|
Docs:
|
"SUMMARY OF FINANCIAL RESULTS FOR FISCAL YEAR ENDED JUNE 30, 2022 -1- At June 30, 2022, Kintara had cash and cash equivalents of approximately $11.8 million. During the year ended June 30, 2022, the Company completed two registered direct offerings for aggregate net proceeds to the Company of approximately $21.6 million. For the year ended June 30, 2022, Kintara reported a net loss of approximately $22.7 million, or $0.52 per share, compared to a net loss of approximately $38.3 million, or $1.60 per share, for the year ended June 30, 2021. The decreased net loss for the year ended June 30, 2022 compared to the year ended June 30, 2021 was largely due to the recognition of $16.1 million of non-cash expenses related to the acquisition of in-process research and development costs associated wi..." |
|
| 09/27/2022 |
10-K
| Annual Report for the period ended June 30, 2022 |
| 08/03/2022 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"PURCHASE AGREEMENT PURCHASE AGREEMENT , dated as of August 2, 2022, by and between KINTARA THERAPEUTICS, INC., a Nevada corporation , LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company . WHEREAS: Subject to the terms and conditions set forth in this Agreement, the Company wishes to sell to the Investor, and the Investor wishes to buy from the Company, up to Twenty Million Dollars of the Company's common stock, par value $0.001 per share . The shares of Common Stock to be purchased hereunder are referred to herein as the "Purchase Shares." NOW THEREFORE, in consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and the Investor hereby a...",
"REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT , dated as of August 2, 2022, by and between KINTARA THERAPEUTICS, INC., a Nevada corporation , and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company . Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Purchase Agreement by and between the parties hereto, dated as of the date hereof . WHEREAS: A. Upon the terms and subject to the conditions of the Purchase Agreement, the Company has agreed to issue to the Investor, and the Investor has agreed to purchase, up to Twenty Million Dollars of the Company's common stock, par value $0.001 per share , pursuant to the Purchase Agreement , and the Company has agreed to issue to the Investor 1,630,191 shares ...",
"Kintara Therapeutics Enters Into Equity Purchase Agreement for Up to $20 Million with Lincoln Park Capital" |
|
| 08/03/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 06/22/2022 |
8-K
| Quarterly results |
| 06/16/2022 |
8-K
| Quarterly results |
| 06/03/2022 |
8-K
| Quarterly results |
| 05/24/2022 |
8-K
| Quarterly results |
| 05/13/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/13/2022 |
8-K
| Quarterly results |
|
|
|